Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the weight loss drugs market, status of the weight loss drug pill, revised ...

David Ricks “We have said it’s not for us right now,” said Ricks. Reuters noted that Ricks is much bolder than his predecessors in terms of acquisitions, after years when Lilly tried to make ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Eli Lilly forecasts $45 billion in 2024 revenue, a 32% growth but $400 million below Q3 guidance. Mounjaro and Zepbound expected to contribute $3.5 billion and $1.9 billion, respectively, to 2024 ...

Now, though, Lilly chief executive officer David Ricks says he is considering expanding the vial offering. Lilly has been offering the vials only to patients paying on their own without insurance ...

12:20 p.m. ET Late Tuesday, Eli Lilly CEO David Ricks took to the stage at the J.P. Morgan Healthcare Conference to explain his views of the booming GLP-1 space. Earlier in the day, Lilly warned ...

Buried in the news from last month was an interesting nugget posted by Fierce Pharma: “Following a dinner at Trump’s Mar-a-Lago estate last week, Eli Lilly CEO David Ricks pointed to raising ...

Heading into fiscal 2025, CEO David Ricks said the company expects sales of weight-loss drugs will continue growing, and noted that it expects "to produce at least 60% more salable doses" of the drugs ...